2 Must-Have Small Biotechs For The Third Quarter


It has been a dismal opening six months for the biotech sector as the space continues to be weak and has been in decline since last summer. However, we have seen an uptick in M&A activity over the past two months that could bode well for a stronger performance in second half of the year.



from Biotech News